16th Annual
Managed Markets & Account Management Strategies Conference
October 29-30, 2024 | New Orleans, LA
Royal Sonesta New Orleans
16th Annual
Managed Markets & Account Management Strategies Conference
October 29-30, 2024
New Orleans, LA
Royal Sonesta New Orleans
Enhancing Access Strategies And Formulary Coverage Through A Thorough Understanding Of The Impact of the Inflation Reduction Act, Forecasted Legislative Changes And Coverage Trends for Cell & Gene Therapy Products
Marc Cohen
Manager, Provider Partnerships & Clinical Program Development
BLUE CROSS BLUE SHIELD MICHIGAN
Matthew Fickie
Senior Medical Director
HIGHMARK
Christina Barrington
VP, Chief Pharmacy Officer
PRIORITY HEALTH
Anna Wetherbee
Director, Strategic Planning & Performance
BLUE CROSS BLUE SHIELD CALIFORNIA
Steven Boyd
EVP & Co-Founder
LIVINITI, LLC.
Lee Washington
Senior Medical Director
AETNA
Jeff Henderson
VP, Head of Global Market Access, Reimbursement & Distribution
IRONWOOD PHARMACEUTICALS
Andrew Erickson
Senior Director, National Accounts
HERON THERAPEUTICS
Josh Rich
Formerly Executive Director, Market Access Accounts
LYKOS THERAPEUTICS
Edward McAdam
Director, Government Pricing, Contracting Operations & Analytics,
INDIVIOR
Kevin Mead
Director, Strategic Accounts
NOVO NORDISK
Greg Apostol
VP, and Head of Market Access
ALKERMES
Brian Cuffel
VP and Head Market Access, Oncology
BAYER
Monica Chmielewski
Partner
FOLEY & LARDNER LLP
Hillary Stemple
Partner
ARENTFOX SCHIFF LLP
Danielle Pettigrew
Director, Corporate Accounts
PARTNER THERAPEUTICS
Jennifer Garofolo
Senior Director, Market Access
VERTEX
Mark Duddy
Senior Director, Payer Account Management
CYTOKINETICS
8:00 REGISTRATION & WELCOME COFFEE
8:50 CHAIRPERSON’S OPENING REMARKS
9:00 OPENING ICE BREAKER: SUCCESSES AND CHALLENGES OF THE MANAGED CARE LANDSCAPE
This interactive ice breaker will open the event with an opportunity for all participants to move around the conference room with the goal of meeting other delegates and engaging in swift discussions. The audience is encouraged to briefly exchange perspectives on the daily challenges of market access and account management, discussing intricacies associated with the evolution of the managed care environment. Furthermore, participants in this warm-up session are also given the opportunity to directly build contacts.
9:30 KEYNOTE PANEL DISCUSSION: BREAKING DOWN THE CURRENT INFLUENCES IMPACTING MANAGED MARKET OPERATIONAL STRATEGIES
• Insights in the payer and industry impact of the Inflation Reduction Act
• Decoding current and pending legislation with potential impact to industry
• Future potential of technology and AI capabilities within account management
• Continued evolution of payer, PBM and specialty pharmacy landscapes
• Overall importance of defining total cost of care vs. drug costs
Jeff Henderson, IRONWOOD PHARMACEUTICALS
Andrew Erickson, HERON THERAPEUTICS
*Additional Panelists to be Announced
10:15 NETWORKING & COFFEE BREAK
10:45 LEGAL PERSPECTIVE: MANAGED CARE & MANAGED MARKETS FEDERAL & STATE LEVEL LEGISLATIVE UPDATE
• Currently pending & proposed federal level legislative bills
• Identifying critical state level legislative decisions
• Policy actions in considerations for CMS and biosimilars
Monica Chmielewski, Partner
FOLEY & LARDNER LLP
11:30 PAYER FIRESIDE CHAT: EXAMINATION OF THE EVOLVING MARKET DYNAMICS IN MANAGED CARE OPERATIONS
• Payer outlook of changes related to the implementation of IRA provisions
• Insights into expectations and requirements for showcasing product value
• Perspective on the future of AI utilization and impact in managed care operations
• Therapeutic coverage trends for CG&T therapies and increasing digital health portfolios
Marc Cohen, BLUE CROSS BLUE SHIELD MICHIGAN
Matthew Fickie, HIGHMARK
Christina Barrington, PRIORITY HEALTH
Anna Wetherbee, BLUE CROSS BLUE SHIELD CALIFORNIA
Lee Washington, AETNA
12:30 LUNCHEON BREAK
2:00 DISCUSSION: OPTIMAL MARKET ACCESS THROUGH PROACTIVE & REACTIVE IRA STRATEGIES
• Strategies for medicare high-spend mature drug negotiation practices
• Steering new CMS inflation rebates for Part B drugs and D drugs
• Implementing HHS-negotiated price for eligible Medicare patients across settings
• Pharmacy-dispensed drugs in Part D
• Hospital and physician-administered Part B drugs
• HHS 2025 selection & negotiation of Part D & B mature drugs
Brian Cuffel, VP and Head Market Access, Oncology
BAYER
2:45 DISCUSSION: DECODING REGULATORY LANGUAGE AND COMPLIANCE WITHIN THE 340B PROGRAM
• Review ongoing litigation and enforcement trends
• Change in administration’s impact on 340B oversight
• Clarification of confusion regarding 340B language
Hillary Stemple, Partner
ARENTFOX SCHIFF LLP
3:30 VIRTUAL NETWORKING & COFFEE BREAK
4:00 DISCUSSION: SMALL BIOPHARMA OPPORTUNITIES FOR MAXIMIZING PBM READINESS
• Maximizing lean teams and resources for optimal market access performance
• Strategies to shorten the product launch to PBM acceptance pipeline
• Aligning PBM value expectations with small biopharma negotiation strategies
Josh Rich, Formerly Executive Director, Market Access Accounts
LYKOS THERAPEUTICS
4:45 DISCUSSION TWO: INTRICACIES OF NAVIGATING PRE-APPROVAL COVERAGE PROCESSES
• Timeline considerations for initiating pre-approval payer conversations
• Effect of increased usage of accelerated approval pathways on pre-approval processes
• Gathering and building impactful early stage data for pre-approval meetings
• Early economic models
• Value drivers
• Discerning payer’s expectations and requirements for pre-approval discussions
Mark Duddy, Senior Director, Payer Account Management
CYTOKINETICS
5:30 Closing Remarks & End of Day 1
Day Two Agenda
Thursday, October 30
8:30 REGISTRATION & WELCOME COFFEE
8:50 CHAIRPERSON’S OPENING REMARKS
9:00 PBM FIRESIDE CHAT: EVALUATION OF BUSINESS & INDUSTRY TRENDS FRAMING THE FUTURE OF MANAGED CARE
• Strategies for improving health equity and healthcare access
• Insights into challenges and management of specific therapeutic markets
» Cell & gene therapy
» Rare disease products
» Biosimilars
• Ripple effect of the IRA on all key product stakeholders within healthcare industry
• Assessment and perspective on current transparency initiatives
• Intricacies associated with the manufacturer rebate negotiations
Steven Boyd, EVP & Co-Founder
LIVINITI, LLC.
9:45 LEGAL PERSPECTIVE: HEALTH POLICY UPDATE ON INFLATION REDUCTION ACT (IRA) OPERATIONALIZATION AND IMPACT
• Critical policy provisions and impact for manufacturers
• Timeline and implementation deadline frameworks
• Response strategies from PBMs and health plans
• Immediate and downstream impact of Medicare price negotiations provision
• Assessing the redesign of Medicare Part D benefits
*Presenter to be Announced
10:30 NETWORKING & COFFEE BREAK
11:00 DISCUSSION: EVALUATION OF THE MARKET ACCESS LANDSCAPE FOR GLP-1 THERAPIES
• Current step edits and restrictions in place for GLP-1 products
• Coverage trends for GLP-1 therapies in the US vs. EU
• Manufacturer strategies to increase patient accessibility
Kevin Mead, Director, Strategic Accounts
NOVO NORDISK
11:45 THERAPEUTIC SPOTLIGHT: UPDATE ON THE CELL & GENE THERAPY (C>) LANDSCAPES
• Exploring the evolution of C> from past to present
• Assessing coverage trends across the C> ecosystems
• Negotiation strategies for C> managed markets contracts
Jennifer Garofolo, Senior Director, Market Access
VERTEX
12:30 LUNCHEON BREAK
1:30 DISCUSSION: INTRICACIES ASSOCIATED WITH UTILIZATION CONTROLS FOR MEDICAL BENEFIT MANAGEMENT PRODUCTS
• Current medical benefit management coverage landscape
• Medical benefit utilization management techniques
• Outreach and communication strategies for medical benefit products
• Patient assistance & access possibilities for medical benefit therapies
Danielle Pettigrew, Director, Corporate Accounts
PARTNER THERAPEUTICS
2:15 DISCUSSION: IMPACT OF INTEGRATING CUSTOMER INSIGHTS ON OVERALL COVERAGE STRATEGY
• Strategies and processes for collecting data and feedback
• Synthesizing feedback and information into usable insights
• Understanding the long term importance of translating customer insights
• Fusing insights into current value propositions and information packets
Edward McAdam, Director, Government Pricing, Contracting Operations & Analytics
INDIVIOR
3:00 DISCUSSION: STRATEGIES FOR LARGE HEALTH SYSTEM & IDN ACCOUNT MANAGEMENT
• Customizing value propositions for the needs of large health systems
• Establishing timelines and methods of communication for IDN clients
• Differentiating informational needs of larger health systems
Greg Apostol, VP, and Head of Market Access
ALKERMES
3:45 Closing Remarks & Conference Conclusion
Previous Attendees Include:
Corporate Account Director, ACORDA THERAPEUTICS
Senior Director of National Accounts, AGIOS PHARMA
VP Market Access Strategy & Marketing, ALKERMES
VP, Market Access, Trade, & Patient Services, AVEO ONCOLOGY
Director, Health Systems, BAYER
Family Access Manager Rare Disease, BIOGEN
Program Director, Specialty Pharmacy, CAREFIRST
Director of Oncology GPO/Speciality Pharmacy, EISAI
Head of Market Access Insights, EMD SERONO
Vice President, Pharmacy Management, EXCELLUS BCBS
Product & Portfolio Strategy Director, GLAXOSMITHKLINE
Pharmaceutical Manufacturer Relations Director, HIGHMARK
Executive Medical Director. Population Health, HORIZON BCBS
National Director, Market Access, INDIVIOR PLC
Director, Strategic Accounts, KINIKSA PHARMACEUTICALS
Corporate Account Manager, KYOWA KIRIN
Director, Regional Accounts, MALLINCKRODT
Associate Director, Corporate Accounts, MITSUBISHI TANABE
Executive Director, NASP
National Account Executive, NEUROCRINE BIOSCIENCES
Medical Accounts Director, NOVO NORDISK
Regional Medical Director, OSCAR HEALTH
Senior Director, National Accounts, PARTNER THERAPEUTICS
Regional Account Director, PFIZER
Director of National and Regional Accounts, RADIUS HEALTH
Regional Account Manager, RELYPSA, INC
Director, Value and Access, SANOFI GENZYME
VP of Global Market Access, SUMMIT THERAPEUTICS
National Account Director, SUNOVION PHARMACEUTICALS
US Lead, Regional Payer Team, TAKEDA ONCOLOGY
Director of National Accounts, THERAPEUTICS MD
Access Accelerator Lead, UCB
Vice President of Market Access, VELOXIS PHARMACEUTICALS
VP & Head of Global Real World Evidence, VERTEX
National Account Director, VIELA BIO
Director, National Accounts, ZOGENIX
….And Many Many More
Who should attend:
Executives that will find this program of greatest relevance are those currently working to enhance payer and managed markets relations within pharmaceutical and biotechnology corporations. Job titles of those executives that will find this program to be most applicable to their job functions include:
Job titles for this meeting include:
• Managed Markets
• Managed Care
• National Accounts
• Regional Accounts
• Payer Relations
